New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
10:03 EDTMS, SLW, PDCE, EXPR, EA, HRC, PVA, MMC, GCI, CHD, ITRI, DO, DELL, CG, AGNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Outperform from Market Perform at JMP Securities... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Dell (DELL) upgraded to Neutral from Sell at Citigroup... Express (EXPR) upgraded to Overweight from Neutral at JPMorgan... Gannett (GCI) upgraded to Buy from Neutral at Citigroup... Marsh & McLennan (MMC) upgraded to Buy from Neutral at Goldman... PDC Energy (PDCE) upgraded to Buy from Hold at Miller Tabak... Diamond Offshore (DO) upgraded to Outperform from Sector Perform at Iberia... Penn Virginia (PVA) upgraded to Outperform from Sector Perform at Howard Weil... Silver Wheaton (SLW) upgraded to Outperform from Neutral at Credit Suisse... Itron (ITRI) upgraded to Buy from Hold at Argus... Hill-Rom (HRC) upgraded to Conviction Buy from Buy at Goldman... Morgan Stanley (MS) upgraded to Neutral from Reduce at SunTrust... Church & Dwight (CHD) upgraded to Outperform from Underperform at CLSA... Electronic Arts (EA) upgraded to Buy from Neutral at Sterne Agee.
News For AGN;CG;GCI;EXPR;DELL;MMC;PDCE;DO;PVA;SLW;ITRI;HRC;MS;CHD;EA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 17, 2015
12:23 EDTHRC, AGNOn The Fly: Top stock stories at midday
Subscribe for More Information
10:44 EDTAGNSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
09:46 EDTEAJefferies to hold company meetings at E3 Expo
Subscribe for More Information
09:25 EDTAGNIronwood slips after Synergy announces data on constipation drug
Shares of Ironwood (IRWD) are lower in pre-market trading after Synergy Pharmaceuticals (SGYP) announced top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in adult patients with chronic idiopathic constipation. Plecanatide was safe and well tolerated at both doses, Synergy said, noting that the most common adverse event was diarrhea, which occurred in 5.9% of patients in 3.0 mg and 5.5% of patients in 6.0 mg dose groups. Ironwood’s competing Linzess drug had a 16% diarrhea rate for CIC patients, according to its FDA label. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). Ironwood shares are down 45c, or 3.7%, to $11.75 in pre-market trading.
09:16 EDTAGNAllergan buyout of KYTHERA boosts aesthetics portfolio, says BMO Capital
BMO Capital says Allergan's (AGN) buyout of KYTHERA (KYTH) builds out the company's aesthetics portfolio. KYTHERA's double chin treatment Kybella "could be a game changer in contouring," and there is no company better suited to make that happen than Allergan, BMO tells investors in a research note. The firm keeps an Outperform rating on Allergan with a $378 price target.
07:44 EDTAGNKYTHERA volatility low into Allergan acquiring for approximately $2.1B
Subscribe for More Information
07:32 EDTHRCHill-Rom to host conference call
Subscribe for More Information
07:21 EDTAGNGeneric ADHD drugs still sold despite FDA non-equivalance finding, NYT reports
The FDA announced last November that two generic versions of Johnson & Johnson's (JNJ) Concerta ADHD drug, one made by Mallinckrodt (MNK) and the other by UCB, could no longer be considered the equivalent of the branded drug after tests and analyses suggested that their effectiveness began to wear off much more quickly, but the drugs are still being sold despite an FDA mandated deadline having passed for the companies to either prove the drugs were equivalent or remove them from the market, said The New York Times. The report noted a third generic product, sold by Actavis (AGN), was found to be equivalent to the branded Concerta. Reference Link
07:19 EDTEAPiper Jaffray to hold company meetings
Piper Meetings @ E3 Conference will be held in Los Angeles on June 17.
07:15 EDTAGNAllergan to host conference call
Conference call to discuss a definitive agreement to acquire KYTHERA Biopharmaceuticals-(KYTH) will be held at 8:30 am on June 17. Webcast Link
07:09 EDTHRCHill-Rom reaffirms FY15 adjusted EPS view $2.50-$2.54, consensus $2.53
Subscribe for More Information
07:07 EDTHRCHill-Rom reaffirms Q3 adjusted EPS view 58c-61c, consensus 61c
Subscribe for More Information
07:06 EDTMSNoble CEO fires back at critics of company’s accounting practices, WSJ says
Noble Group (NOBGY) CEO Yusuf Alireza disputed allegations about the company’s accounting practices, particularly that it is hiding the true nature of its debt and improperly valuing its 13% stake in Australian coal miner Yancoal, the Wall Street Journal reports. In a letter to former longtime Morgan Stanley (MS) banker Michael Dee, Alireza said that the company’s evaluation of Yancoal is “reasonable and consistent with market practice and accounting policies” and that “any suggestion otherwise is ill-informed and factually incorrect,” the report says. “As an associate company, we must rely on a cash flow model to value our stake, which is consistent with market practice in the mining industry,” the Noble CEO added, the report says. Reference Link
07:06 EDTHRCHill-Rom to acquire Welch Allyn for about $2.05B in cash and stock
Subscribe for More Information
07:04 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
Subscribe for More Information
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:03 EDTHRCHill-Rom to acquire Welch Allyn for about $2.05B in cash and stock
07:03 EDTAGNAllergan agrees to acquire KYTHERA for $75 per share or approximately $2.1B
Subscribe for More Information
07:02 EDTAGNAllergan to acquire KYTHERA for $75 per share, or $2.1B
06:48 EDTMSMore big banks waiving overdraft fees, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use